Axonics, Inc. (NASDAQ:AXNX – Get Free Report) has been given a consensus recommendation of “Hold” by the twelve research firms that are currently covering the firm, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year […]
Axonics, Inc. today announced that it has entered into a definitive agreement to be acquired by Boston Scientific Corporation for $71 in cash per share, representing an equity value of.
Axonics, Inc. , a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported preliminary unaudited.
Axonics, Inc. (AXNX) Acquired by Boston Scientific (BSX) for $71/sh or $3.7B streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.